XML 66 R48.htm IDEA: XBRL DOCUMENT
v3.19.2

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands |  |  |  |  |  |  |  |  |  | 11 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 30, 2019 | Jun. 04, 2019 | Aug. 01, 2018 | Jul. 02, 2018 | Feb. 01, 2018 | Jan. 02, 2018 | Sep. 05, 2017 | Aug. 01, 2016 | Jul. 01, 2016 | Jun. 30, 2019 | Jun. 30, 2019 | Jun. 30, 2019 | Jun. 30, 2019 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2017
Payments to Acquire Businesses, Net of Cash Acquired, Total |  |  |  |  |  |  |  |  |  |  |  | $ 289,492 |  |  | $ 67,851 | $ 253,785
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (26,600) | $ (11,800)
Business Combination, Contingent Consideration, Liability, Total | $ 12,600 |  |  |  |  |  |  |  |  | $ 12,600 | $ 12,600 | 12,600 | $ 12,600 | $ 12,600 |  |
QT Holdings Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired, Total |  |  |  | $ 20,404 |  |  |  |  |  |  |  |  |  | 20,462 |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 51,000 |  |  | 51,000 |  |  |  |  |  | 51,000 | 51,000 | 51,000 | 51,000 | 51,000 |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |
Goodwill, Purchase Accounting Adjustments |  |  |  |  |  |  |  |  |  |  |  |  | 4,700 | 4,691 |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 12,256 |  |  | 20,000 |  |  |  |  |  | 12,256 | 12,256 | 12,256 | 12,256 | 12,256 |  |
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles |  |  |  |  |  |  |  |  |  |  |  |  |  | (7,744) |  |
Business Combination, Consideration Transferred, Total |  |  |  | 25,604 |  |  |  |  |  |  |  |  |  | 25,762 |  |
Business Combination, Consideration Transferred, Liabilities Incurred |  |  |  | $ 5,200 |  |  |  |  |  |  |  |  |  | 5,300 |  |
QT Holdings Corporation [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 14 years |  |  |  |  |  |  |  |  |  |  |  |
Exosome Diagnostics, Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired, Total | 251,623 |  | $ 251,825 |  |  |  |  |  |  | 251,600 |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 325,000 |  | 325,000 |  |  |  |  |  |  | 325,000 | 325,000 | $ 325,000 | 325,000 | 325,000 |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill, Purchase Accounting Adjustments |  |  |  |  |  |  |  |  |  |  | 8,770 |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |  |  |  |  |  |  |  |  |  |  | 2,000 |  |  |  |  |
Business Combination, Consideration Transferred, Total |  |  | 253,625 |  |  |  |  |  |  |  | 255,423 |  |  |  |  |
Business Combination, Consideration Transferred, Liabilities Incurred |  |  | 1,800 |  |  |  |  |  |  |  | 3,800 |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |  |  | 250,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |  |  | 45,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |  |  | 30,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  |  |  |  |  | 15 years |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  | 180,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  |  |  |  |  | 15 years |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 58,000 |  |  |  |  |  |  |  |  | 58,000 | 58,000 | $ 58,000 | 58,000 | 58,000 |  |
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles |  |  |  |  |  |  |  |  |  |  | 58,000 |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Developed Technology [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 105,000 |  |  |  |  |  |  |  |  | 105,000 | 105,000 | $ 105,000 | 105,000 | 105,000 |  |
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles |  |  |  |  |  |  |  |  |  |  | (75,000) |  |  |  |  |
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  |  |  |  |  | 14 years |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 2,300 |  |  |  |  |  |  |  |  | 2,300 | 2,300 | $ 2,300 | 2,300 | 2,300 |  |
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles |  |  |  |  |  |  |  |  |  |  | 2,300 |  |  |  |  |
B-MoGen [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired, Total |  | $ 17,448 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 38,000 | 38,000 |  |  |  |  |  |  |  | $ 38,000 | $ 38,000 | 38,000 | $ 38,000 | $ 38,000 |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value |  | 1,400 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain |  | 3,700 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Liabilities Incurred |  | $ 5,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |
B-MoGen [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  | 14 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  | $ 14,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
B-MoGen [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  | $ 400 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trevigen Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired, Total |  |  |  |  |  |  | $ 10,600 |  |  |  |  | 10,644 |  |  |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount |  |  |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Total |  |  |  |  |  |  |  |  |  |  |  | 10,644 |  |  |  |
Business Combination, Consideration Transferred, Liabilities Incurred |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atlanta Biologicals [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired, Total |  |  |  |  |  |  |  |  |  |  |  | 51,274 |  |  |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount |  |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Total |  |  |  |  |  | $ 51,300 |  |  |  |  |  | 51,274 |  |  |  |
Business Combination, Consideration Transferred, Liabilities Incurred |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atlanta Biologicals [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  | 13 years |  |  |  |  |  |  |  |  |  |
Atlanta Biologicals [Member] | Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  | 15 years |  |  |  |  |  |  |  |  |  |
Atlanta Biologicals [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  | 12 years |  |  |  |  |  |  |  |  |  |
Eurocell Diagnostics, SAS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired, Total |  |  |  |  |  |  |  |  |  |  |  | 5,933 |  |  |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Total |  |  |  |  | 7,300 |  |  |  |  |  |  | 7,329 |  |  |  |
Payments to Acquire Businesses, Gross |  |  |  |  | 6,000 |  |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Liabilities Incurred |  |  |  |  | $ 1,300 |  |  |  |  |  |  | 1,396 |  |  |  |
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  | 7 years |  |  |  |  |  |  |  |  |  |  |
Advanced Cell Diagnostics (ACD) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired, Total |  |  |  |  |  |  |  | $ 247,000 |  |  |  | 247,038 |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |  |  |  |  |  |  |  | 75,000 |  |  |  |  |  |  |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Total |  |  |  |  |  |  |  |  |  |  |  | 287,638 |  |  |  |
Payments to Acquire Businesses, Gross |  |  |  |  |  |  |  | 258,000 |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Liabilities Incurred |  |  |  |  |  |  |  | $ 11,000 |  |  |  | 3,600 |  |  |  |
Business Combination, Consideration Transferred, Employee Vesting Period |  |  |  |  |  |  |  | 1 year 180 days |  |  |  |  |  |  |  |
Advanced Cell Diagnostics (ACD) [Member] | Pre-acquisition Services [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Liabilities Incurred |  |  |  |  |  |  |  | $ 3,600 |  |  |  |  |  |  |  |
Advanced Cell Diagnostics (ACD) [Member] | Future Services [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Liabilities Incurred |  |  |  |  |  |  |  | 7,400 |  |  |  |  |  |  |  |
Advanced Cell Diagnostics (ACD) [Member] | The 2016 Revenue Equal or Exceed $30 Milliom [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Total |  |  |  |  |  |  |  | 25,000 |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue |  |  |  |  |  |  |  | 30,000 |  |  |  |  |  |  |  |
Advanced Cell Diagnostics (ACD) [Member] | The 2017 Revenues Equal or Exceed $45 Million [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Total |  |  |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue |  |  |  |  |  |  |  | $ 45,000 |  |  |  |  |  |  |  |
Space [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired, Total |  |  |  |  |  |  |  |  | $ 6,700 |  |  | 6,747 |  |  |  |
Business Acquisition, Goodwill, Expected Tax Deductible Amount |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Total |  |  |  |  |  |  |  |  |  |  |  | 9,003 |  |  |  |
Payments to Acquire Businesses, Gross |  |  |  |  |  |  |  |  | 9,000 |  |  |  |  |  |  |
Business Combination, Consideration Transferred, Liabilities Incurred |  |  |  |  |  |  |  |  | $ 2,300 |  |  | $ 2,256 |  |  |  |

X
- Definition The period in which the employee must be employed by the Company to receive payment for unvested shares. + References No definition available. + Details
Name: | tech_BusinessCombinationConsiderationTransferredEmployeeVestingPeriod
Namespace Prefix: | tech_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue that will trigger the contingent consideration liability in a business combination. + References No definition available. + Details
Name: | tech_BusinessCombinationContingentConsiderationLiabilityTriggerAmountOfRevenue
Namespace Prefix: | tech_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages, before remeasurement to fair value. + References No definition available. + Details
Name: | tech_BusinessCombinationStepAcquisitionEquityInterestInAcquireeBeforeRemeasurementToFairValue
Namespace Prefix: | tech_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(3) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4A -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=SL65897772-128472 + Details
Name: | us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -URI http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillPurchaseAccountingAdjustments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_QTHoldingsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_ExosomeDiagnosticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=tech_CalendarYear2020EBITABetween45MillionAnd58MillionOrGreaterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=tech_CalendarYear2022EBITAForANewInstrumentProductBetween54MillionAnd70MillionOrGreaterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=tech_CalendarYear2022EBITAForRemainingBusinessBetween150MillionAnd190MillionOrGreaterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tech_DevelopedTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_BMoGenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_TrevigenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_AtlantaBiologicalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_EurocellDiagnosticsSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_AdvancedCellDiagnosticsACDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_NatureOfExpenseAxis=tech_PreacquisitionServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_NatureOfExpenseAxis=tech_FutureServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=tech_The2016RevenueEqualOrExceed30MilliomMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=tech_The2017RevenuesEqualOrExceed45MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_SpaceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |